Psychiatry

News

FDA kicks off review of Karuna’s schizophrenia drug KarXT

Karuna Therapeutics said this morning that the FDA has formally started its review of KarXT, aiming to become the first drug to reach the market for schizophrenia with a n

News

Otsuka makes psychedelics play, buying Mindset

Japanese pharma group Otsuka has signed an agreement to acquire Canada's Mindset Pharma, a specialist in psychedelic medicines for neuropsychiatric disorders.

News

Zuranolone cleared for post-partum depression, but not MDD

Biogen and Sage Therapeutics' zuranolone has become the first oral drug to be approved by the FDA for post-partum depression (PPD), but the US regulator turned down a requ

News

Sumitomo's novel schizophrenia drug flunks phase 3 test

After decades of stagnation in the drug treatment of schizophrenia, a handful of new therapies have raised hopes of improvement – but one of them has just failed a pair of

News

Small study raises hopes of psilocybin role in anorexia

A small clinical trial has provided the first evidence that the psychedelic medicine psilocybin may have a role to play in the treatment of anorexia nervosa, an eating dis

News

Fake Dictionary, Dictionary definition of the word Schizophrenia.

Newron says pivotal treatment-resistant schizophrenia trial ...

Encouraged by new data, Newron Pharmaceuticals has said it will start a registration study of would-be blockbuster evenamide in treatment-resistant schizophrenia (TRS) later this year.

FDA kicks off review of Karuna’s schizophrenia drug KarXT

Otsuka makes psychedelics play, buying Mindset

Zuranolone cleared for post-partum depression, but not MDD

Sumitomo's novel schizophrenia drug flunks phase 3 test

Small study raises hopes of psilocybin role in anorexia

Newron says pivotal treatment-resistant schizophrenia trial ...

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Psychiatry

Editor's Picks